Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Celecoxib's effect on inflammatory response in patients receiving thoracic and abdominal surgery (Phase II study)

Next Previous
Trial Profile

Celecoxib's effect on inflammatory response in patients receiving thoracic and abdominal surgery (Phase II study)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Celecoxib (Primary)
  • Indications Inflammation
  • Focus Therapeutic Use

Most Recent Events

  • 13 Jan 2017 Primary endpoint has not been met. (Urine prostaglandin E metabolite at 48 hours following surgery commencement as measured by immunoassay), as per the results published in the Canadian Journal of Anesthesia.
  • 13 Jan 2017 Primary endpoint has not been met. (Plasma prostaglandin E metabolite at 48 hours following surgery commencement as measured by immunoassay), as per the results published in the Canadian Journal of Anesthesia.
  • 13 Jan 2017 Results published in the Canadian Journal of Anesthesia.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top